3 news items
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
KPTI
1 Jun 24
TP53 wild-type patients were nausea (90%), vomiting (60%) and diarrhea (45%), the majority of which were
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
KPTI
8 May 24
and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
KPTI
8 May 24
majority of our debt obligations well beyond the planned readouts and potential approvals of our three ongoing Phase 3 programs," said
- Prev
- 1
- Next